10-Q quarterly report · filed Oct 23, 2026

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Q3 2026 10-Q Quarterly Report

Short answer

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed its Q3 2026 10-Q quarterly report on Oct 23, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $411M (up 2.3% year over year) with net income of $15M.

Q3 2026 key financials · XBRL

Revenue
$411M
+2.3% YoY · −1.8% QoQ
Net income
$15M
+374.8% YoY · +231.3% QoQ
Operating margin
4.6%
EPS (diluted)
$0.19
+371.4% YoY · +216.7% QoQ

Source: XBRL data from the INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Q3 2026 10-Q on SEC EDGAR. USD.

INTEGRA LIFESCIENCES HOLDINGS CORP Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $411.2M, up $9.1M YoY from $402.1M, low-single-digit growth
  • Specialty Surgery $304.1M, up 4% YoY; Tissue Reconstruction $107.1M, down 2%
  • Gross margin 51.0% vs 51.5% YoY; operating expenses 46.4% vs 48.5%
  • Cash $252.3M vs $235.0M at December 31, 2025; nine-month operating cash flow $128.6M vs $38.6M
  • Cincinnati disruption reduced revenue approximately $7M; facility recovery expected during second quarter 2027, SurgiMend relaunch targeted fourth quarter 2026

Risk Factors

  • No material changes to risk factors from the December 31, 2025 Form 10-K
  • Carried-forward risks remain governed by the previously filed annual report

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other INTEGRA LIFESCIENCES HOLDINGS CORP quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.